ZAREJESTRUJ SIĘ JUŻ DZIŚ!
ilość miejsc ograniczona
REJESTRACJA

PROGRAMME ENG


11:00 - 12:00
REGISTRATION
12:00 - 12:30
OPENING CEREMONY
12:30 - 14:15
EUROPEAN GUIDELINES ON NET MANAGEMENT IN POLISH REALITY (ENETS STANDARDS OF CARE IN NEUROENDOCRINE TUMORS AND UNMET MEDICAL NEEDS) - PART I
Prowadzący: Prof. G. Rydzewska (Warsaw), Prof. B. Kos-Kudła (Katowice)
12:30 - 12:45
in pathology diagnostics
Prof. A. Nasierowska - Guttmejer (Warsaw)
12:45 - 13:00
imaging diagnostics
Ass. Prof. J. Pilch-Kowalczyk
13:00 - 13:15
in radioisotope diagnostics and treatment
Prof. G. Kamiński (Warsaw)
13:15 - 13:30
in gastric and duodenal NETs
Prof. G. Rydzewska (Warsaw)
13:30 - 13:45
in small bowel NETs
Prof. T. Bednarczuk (Warsaw)
13:45 - 14:15
DISCUSSION
14:15 - 14:45
Coffee Break
14:45 - 16:45
SESSION II - CONTROVERSIES: EUROPEAN GUIDELINES ON NET MANAGEMENT IN POLISH REALITY (ENETS STANDARDS OF CARE IN NEUROENDOCRINE TUMORS AND UNMET MEDICAL NEEDS) - PART II
Prowadzący: Chair: Prof. B. Kos-Kudła (Katowice), Prof. M. Bolanowski (Wrocław)
14:45 - 15:00
in colorectal NETs
Prof. M. Szczepkowski (Warsaw)
15:00 - 15:15
functioning and non-functioning pancreatic NETs
Prof. B. Kos-Kudła (Katowice)
15:15 - 15:30
in NET G3/ NEC
Dr E. Wachuła (Katowice)
15:30 - 15:45
in advanced NETs with distant metastases
15:45 - 16:00
in appendiceal NETs
Ass. Prof. A. Bałdys-Waligórska (Kraków)
16:00 - 16:15
in pulmonary carcinoids
Prof. D. Handkiewicz- Junak (Gliwice)
16:15 - 16:45
DISCUSSION
16:45 - 17:00
Coffee Break
17:00 - 17:40
SESSION III: OXFORD DEBATE: MONOTHERAPY VS. COMBINED THERAPIES IN GEP-NETs

proposition: Prof J. Ćwikła - PRRT as monotherapy, Ass. Prof. A. Sowa- Staszczak (Kraków) – somatostatin analogues in monotherapy, Dr W. Rogowski (Olsztyn) – targeted molecular therapies in monotherapy

 

opposition: Dr A. Kolasińska-Ćwikła (Warsaw) - PRRT in combinations, Ass. Prof. P. Gut (Poznań) – somatostatin analogues in combination, Dr M. Jarząb (Gliwice) - targeted molecular therapies in combinations

 

Chairperson: Prof. B. Kos-Kudła (Katowice)

 

Adjudicators: Prof. M. Ruchała (Poznań), Prof. G. Kamiński (Warsaw)

09:00 - 10:40
SESSION IV
09:00 - 09:25
Debate – gastric NETs

  • endoscopic treatment – Prof. T. Starzyńska (Szczecin)
  • surgical treatment – Dr A. Cichocki (Warsaw)
09:25 - 09:45
Do locoregional therapies and liver transplantation impact survival in NETs?
09:45 - 10:10
Debate: Removal of primary has favourable impact on survival in NETs with distant metastases

For – Ass. Prof. K. Kuśnierz (Katowice)

Against – Prof. R. Król (Katowice)

10:10 - 10:40
Discussion
10:40 - 11:20
SESSION V TUMOUR BOARD: PANCREATIC NET
10:40 - 11:20

Tumour Board Experts:

Endocrinologist: Prof. R. Junik (Bydgoszcz)

Surgeon: Prof. Z. Stojcev (Katowice)

Oncologist: Dr E. Wachuła (Katowice)

Gastroenterologist: Ass. Prof. K. Gutkowski (Rzeszów)

Nuclear Medicine Specialist: Ass. Prof.. M. Saracyn (Warsaw)

Radiologist: Prof. B. Bobek - Billewicz (Gliwice)

Pathologist: Dr Ł. Liszka (Katowice)

 

 

10:40 - 11:00 Pancreatic NET case presentation - Dr W. Foltyn (Katowice)

 

11:00 - 11:20 Tumour Board discussion

 

11:20 - 11:40
Coffee Break
11:40 - 13:30
SESSION VI - INTERNATIONAL
11:40 - 12:10
Systemic therapy for NETs; Current options and challenges
Prof. M Pavel (Germany)
12:10 - 12:40
Where are we going with our understanding and treatment of NETs in 2019?
Prof. S. Glasberg (Israel)
12:40 - 13:00
PRRT - which treatment line for intestinal and pancreatic NENs?
Dr G. Vivian (UK)
13:00 - 13:30
Debate – gastric NETs
13:30 - 14:30
SESSION VII – POSTER SESSION
13:30 - 14:30
Lunch
14:30 - 15:50
SESSION VIII
14:30 - 14:50
Debate: Should anticoagulation be used in NET management?

• For: Prof. Z. Gaciong (Warsaw)

• Against: Dr A. Kolasińska-Ćwikła (Warsaw)

14:50 - 15:50
EXPERT COMMENTS

1.Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocr Relat Cancer. 2017; 24: R315-R334 - Prof. B. Jarząb (Gliwice)

2. Initial experience with CT-guided high-dose-rate brachytherapy in the multimodality treatment of

neuroendocrine tumor liver metastases. J Vasc Interv Radiol. 2017; 28: 672-682 - Prof. I. Gisterek (Katowice)

3. Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way. EndocrRelat Cancer. 2017; 24: T261-T281 - Dr B. Czartoryska-Arłukowicz (Białystok)

4. Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE) Roquin G et al. Neuroendocrin - Dr A. Boratyn –Nowicka (Katowice)

5. Prognostic Evaluations Tailored to Specific Gastric Neuroendocrine Neoplasms: Analysis Of 200 Cases with Extended Follow-Up. Vanoli A et al. Neuroendocrinology 2018;107:114–126

Ass. Prof. E. Nowakowska-Duława (Katowice)

6. Mesenteric Fibrosis in Midgut Neuroendocrine Tumors: Functionality and Radiological Features.

Rodríguez Laval V. et al. Neuroendocrinology 2018; 106:139–147 - Prof. M. Studniarek (Gdańsk)

15:50 - 16:30
SESSION IX: TUMOUR BOARD: MIDGUT NET
15:50 - 16:30

Tumour Board Experts:

Endocrinologist: Prof. W. Zgliczyński (Warsaw)

Surgeon: Ass. Prof. K. Kuśnierz (Katowice)

Oncologist: Dr A. Boratyn - Nowicka (Katowice)

Gastroenterologist: Ass. Prof. E. Nowakowska - Duława (Katowice)

Nuclear Medicine Specialist: Prof. J. Ćwikła

Radiologist: Prof. M. Studniarek (Gdańsk)

Pathologist: Prof. A. Nasierowska - Guttmejer (Warsaw)

 

 

 

15:50 - 16:10 Midgut NET case presentation

                        Dr A. Lewczuk-Myślicka (Gdańsk)

 

16:10 - 16:30 Tumour Board discussion


Ta strona używa ciasteczek (COOKIES). Zapoznaj się z Polityką prywatności aby dowiedzieć się więcej.
Korzystając ze strony wyrażasz zgodę na używanie cookie, zgodnie z aktualnymi ustawieniami przeglądarki.